caspofungin
PharmacologyBody Surface Area-Based Dosing Regimen of Caspofungin in Children: a Population Pharmacokinetics Confirmatory StudyWe evaluated the population pharmacokinetics of caspofungin in children (2 to 12 years of age). The real-world data from 48 children were best fit by a two-compartment model with first-order elimination.
Clinical TherapeuticsPharmacokinetics of Caspofungin in Critically Ill Patients in Relation to Liver Dysfunction: Differential Impact of Plasma Albumin and Bilirubin LevelsCaspofungin has a liver-dependent metabolism. Reduction of the dose is recommended based on Child-Pugh (C-P) score.
Mechanisms of ResistanceSpontaneous Mutational Frequency and FKS Mutation Rates Vary by Echinocandin Agent against Candida glabrataEchinocandins are front-line agents for treatment of invasive candidiasis. There are no reported agent-specific differences in Candida mutational frequency of resistance or propensity to develop FKS mutations.
- Mechanisms of ResistanceUnderstanding Echinocandin Resistance in the Emerging Pathogen Candida auris
- Experimental TherapeuticsAntifungal Activity of Oleylphosphocholine on In Vitro and In Vivo Candida albicans Biofilms